Founders Financial Securities LLC purchased a new position in shares of Johnson & Johnson (NYSE:JNJ) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 5,620 shares of the company’s stock, valued at approximately $743,000.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. State Street Corp boosted its holdings in Johnson & Johnson by 4.3% during the 1st quarter. State Street Corp now owns 160,223,321 shares of the company’s stock valued at $19,955,806,000 after acquiring an additional 6,656,371 shares during the period. Harbour Capital Advisors LLC boosted its holdings in Johnson & Johnson by 13,327.8% during the 2nd quarter. Harbour Capital Advisors LLC now owns 2,501,472 shares of the company’s stock valued at $18,909,000 after acquiring an additional 2,482,843 shares during the period. Korea Investment CORP boosted its holdings in Johnson & Johnson by 38.9% during the 1st quarter. Korea Investment CORP now owns 2,130,033 shares of the company’s stock valued at $265,296,000 after acquiring an additional 596,134 shares during the period. Bank of Nova Scotia boosted its holdings in Johnson & Johnson by 94.5% during the 1st quarter. Bank of Nova Scotia now owns 1,171,517 shares of the company’s stock valued at $145,914,000 after acquiring an additional 569,313 shares during the period. Finally, Oppenheimer Asset Management Inc. purchased a new position in Johnson & Johnson during the 1st quarter valued at about $65,598,000. Institutional investors and hedge funds own 65.93% of the company’s stock.
A number of equities analysts recently commented on the company. J P Morgan Chase & Co raised their target price on Johnson & Johnson from $140.00 to $148.00 and gave the company an “overweight” rating in a report on Wednesday, August 16th. Jefferies Group LLC set a $145.00 target price on Johnson & Johnson and gave the company a “hold” rating in a report on Tuesday, August 15th. UBS AG restated a “buy” rating and set a $148.00 target price (up from $136.00) on shares of Johnson & Johnson in a report on Wednesday, July 19th. BTIG Research cut Johnson & Johnson from a “neutral” rating to a “sell” rating and set a $110.00 target price for the company. in a report on Friday, July 21st. Finally, Vetr cut Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 target price for the company. in a report on Monday, September 18th. Four investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have issued a buy rating to the company. Johnson & Johnson currently has a consensus rating of “Hold” and an average price target of $143.70.
Shares of Johnson & Johnson (NYSE:JNJ) opened at $139.49 on Wednesday. The firm has a market capitalization of $375,468.03, a PE ratio of 19.57, a PEG ratio of 2.84 and a beta of 0.82. Johnson & Johnson has a 12-month low of $109.32 and a 12-month high of $144.35. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, topping the consensus estimate of $1.80 by $0.10. The company had revenue of $19.65 billion for the quarter, compared to analyst estimates of $19.29 billion. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The firm’s revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.68 earnings per share. research analysts forecast that Johnson & Johnson will post 7.28 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th will be given a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 2.41%. The ex-dividend date of this dividend is Monday, November 27th. Johnson & Johnson’s dividend payout ratio (DPR) is 58.33%.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.